Extended Data Fig. 1: Characterization of anti-CD40 mIgG1 mAb ChiLob 7/4 affinity mutants.
From: Reducing affinity as a strategy to boost immunomodulatory antibody agonism
a, SPR of various ChiLob 7/4 m1 affinity mutants injected at 250, 50, 10, 2, 0.4, and 0 nM binding to CD40ECD. Data representative of 3 independent experiments. b, ChiLob 7/4 m1 affinity mutants were evaluated for their binding affinity for CD40ECD by SPR as indicated in a, with affinity constants (ka, kd and KD) calculated. Fold change indicates affinity change compared with WT ChiLob 7/4 m1. c, Ramos cells were incubated with 0.5 μg/mL of AF647-labelled ChiLob 7/4 h1 and various concentrations of competing ChiLob 7/4 m1 affinity mutants as indicated and then washed and bound AF647-labelled ChiLob 7/4 h1 detected. Means ± SEM, n = 3, data representative of 3 independent experiments.
